Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Point estimates of number needed to treat/screen are insufficient without characterization of their uncertainty.

Pinsky PF.

J Clin Oncol. 2011 Aug 20;29(24):3336; author reply 3337. doi: 10.1200/JCO.2011.36.4554. Epub 2011 Jul 18. No abstract available.

2.

Evidence-based uncertainty: recent trial results on prostate-specific antigen testing and prostate cancer mortality.

Smith DP, Banks E, Clements MS, Gardiner RA, Armstrong BK.

Med J Aust. 2009 Aug 17;191(4):199-200.

PMID:
19705979
3.

Prostate cancer: to screen or not to screen.

Asal NR.

Ethn Dis. 2003 Summer;13(3 Suppl 3):S3-76-81. No abstract available.

PMID:
14552460
4.

The controversy over PSA testing: has anything changed?

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2009 Aug;21(6):1-2. No abstract available.

PMID:
19722309
5.

PSA testing.

Frydenberg M.

Aust Fam Physician. 2003 Jun;32(6):396. No abstract available.

PMID:
12833760
6.

[Timely screening routines for prostatic cancer by Norwegian physicians].

Fosså SD, Eri LM.

Tidsskr Nor Laegeforen. 1999 Oct 10;119(24):3572-6. Norwegian.

PMID:
10563174
7.

Contemporary view of prostate cancer diagnosis and treatment.

Costello AJ.

Aust Fam Physician. 2003 Jun;32(6):396-8. No abstract available.

PMID:
12833761
8.

Screening and early treatment of prostate cancer are accumulating strong evidence and support.

Mettlin C.

Prostate. 2000 May 15;43(3):223-4. No abstract available.

PMID:
10797497
9.

Screening for prostate cancer: have we resolved the controversy?

Zhu X, Roobol MJ, Schröder FH.

Curr Opin Support Palliat Care. 2010 Sep;4(3):121-6. doi: 10.1097/SPC.0b013e32833abc21. Review.

PMID:
20489646
11.

Detection characteristics in randomized prostate screening.

Schröder FH, Roobol MJ.

Clin Cancer Res. 2004 Sep 1;10(17):5641-2. No abstract available.

12.

Mass screening for prostate cancer.

Andersson L.

Acta Oncol. 1998;37(6):513-4. No abstract available.

PMID:
9860308
13.

[Prostate cancer screening].

Saksela E.

Duodecim. 1997;113(9):871. Finnish. No abstract available.

PMID:
11466912
14.

[PSA-based screening for prostatic cancer].

Johansen TE.

Tidsskr Nor Laegeforen. 1999 Oct 10;119(24):3550. Norwegian. No abstract available.

PMID:
10563168
15.

PSA screening for asymptomatic prostate cancer: truth in advertising.

Hahn DL, Roberts RG.

J Fam Pract. 1993 Nov;37(5):432-6. No abstract available.

PMID:
7693858
16.

PSA: prostate-specific antigen, persisting scientific ambiguities.

[No authors listed]

Harv Mens Health Watch. 2009 Jul;13(12):1-6. No abstract available.

PMID:
19718841
17.

[Mass screening for prostate cancer will have to wait. The scientific basis insufficient, more efficient markers necessary].

Damber JE.

Lakartidningen. 2003 Sep 18;100(38):2916-8, 2921. Review. Swedish. No abstract available.

PMID:
14558209
18.

A risk-stratified approach to prostate-specific antigen screening.

Keto CJ, Freedland SJ.

Eur Urol. 2011 Apr;59(4):506-8. doi: 10.1016/j.eururo.2011.01.029. Epub 2011 Jan 25. No abstract available.

PMID:
21292387
19.

Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.

Roemeling S, Kranse R, Vis AN, Gosselaar C, van der Kwast TH, Schröder FH.

Cancer. 2006 Dec 15;107(12):2779-85.

20.

Prostate specific antigen: a useful screening test?

Concato J.

Cancer J. 2000 Apr;6 Suppl 2:S188-92. Review.

PMID:
10803835
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk